

CITATION REPORT

List of articles citing

**NAFLD and MAFLD as emerging causes of HCC: A
populational study**

DOI: 10.1016/j.jhepr.2021.100231
JHEP Reports, 2021, 3, 100231.

Source: <https://exaly.com/paper-pdf/79972139/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
31	The third year. <i>JHEP Reports</i> , 2021 , 3, 100259	10.3	
30	The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	8
29	Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	3
28	Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. <i>Transplant International</i> , 2021 , 34, 1444-1454	3	1
27	Kahweol Induces Apoptosis in Hepatocellular Carcinoma Cells by Inhibiting the Src/mTOR/STAT3 Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
26	Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. <i>Aging</i> , 2021 , 13, 23416-23434	5.6	1
25	Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion. <i>Frontiers in Medicine</i> , 2021 , 8, 789859	4.9	4
24	MAFLD Enhances Clinical Practice for Liver Disease in the Asia-Pacific region. <i>Clinical and Molecular Hepatology</i> , 2021 ,	6.9	4
23	An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
22	Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC.. <i>Frontiers in Oncology</i> , 2021 , 11, 783339	5.3	
21	Impact of Data Mining on HCC Prediction: Survey. <i>Lecture Notes in Networks and Systems</i> , 2022 , 777-784	0.5	
20	Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?. <i>World Journal of Hepatology</i> , 2022 , 14, 158-167	3.4	0
19	Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study.. <i>Frontiers in Oncology</i> , 2022 , 12, 816472	5.3	1
18	Metabolic dysfunction-associated fatty liver disease: a year in review.. <i>Current Opinion in Gastroenterology</i> , 2022 ,	3	3
17	MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients.. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022 , 15, 673-683	3.4	0
16	NAFLD-related hepatocellular carcinoma: The growing challenge.. <i>Hepatology</i> , 2022 ,	11.2	3
15	Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management. <i>Infectious Microbes & Diseases</i> , 2022 , 4, 49-55	1.3	1

14	Geographical similarity and differences in the burden and genetic predisposition of NAFLD.	3
13	Hepatic macrophage mediated immune response in liver steatosis driven carcinogenesis. 12,	0
12	Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations. 9,	0
11	Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?. 1-9	0
10	Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement. 2023 , 15, 637	0
9	Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals.	0
8	The hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for Child-Pugh A patients undergoing curative hepatic resection for single and small hepatocellular carcinoma.	0
7	Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. 2023 , 11, 468	3
6	An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians. 2023 , 11, 586	0
5	The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases. 2023 , 15, 1123	0
4	Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes. 2023 , 13, 558	1
3	Comparison of survival rates as predicted by total tumor volume or tumor burden score in patients with hepatocellular carcinoma concurrent with fatty liver disease and hepatitis B virus. 1-9	0
2	Should we undertake surveillance for HCC in patients with MAFLD?. 2023 , 14, 204201882311603	0
1	Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes. 15, 477-496	0